Iterum Therapeutics Plc Overview
Latest ROE for Iterum Therapeutics Plc: 365.28% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow365.28%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for ITRM is 365.28%. That is above the Healthcare sector average of 11.15%. Investors often review this figure alongside Iterum Therapeutics Plc's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ITRM currently prints 365.28% for ROE, while the sector average sits near 11.15%. That is roughly 3174.8% above the sector mean. Large gaps often invite a closer look at Iterum Therapeutics Plc's growth, margins, and balance sheet.
Return on Equity shows how effectively Iterum Therapeutics Plc converts resources into returns. At 365.28%, ITRM may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ITRM's ROE (365.28%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Iterum Therapeutics Plc's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
